Immunicom, Inc. is a privately held medical technology company with a transformative delivery platform for immuno-oncology that addresses critical unmet patient needs in the treatment of cancer and other oncologic and immunologic disorders.
Immunopheresis® is an entirely novel method of treating cancer. It is a therapeutic delivery platform that consists of cartridges, and in each cartridge is a unique and customized molecule(s) deployed in our high-affinity molecular matrix designed for removing either a single or multiple target components out of plasma, using apheresis. These target components, such as cytokines, growth factors, angiogenesis proteins, anti-antibodies, lipids, and other circulating components, are factors that inhibit the immune system, cause toxicity, and promote disease.
Immunopheresis is a subtractive immunotherapy that removes cancer-promoting factors from plasma without infusing treatment, such as drugs, into the patient’s body. Because no drugs, chemicals, or antibodies are infused into the patient’s body, the subtractive nature of the therapy has been found to have a benign safety profile, unlike the harsh adverse effects often associated with chemo- and immunotherapies. Safe immune activation via Immunopheresis subtractive immunotherapy allows for its use as an adjunct to enhance multiple IO approaches by improving patient response and extending the duration and efficacy of existing IO treatments without added toxicity.
Immunicom’s lead product, the LW-02 Immunopheresis Cartridge, has been awarded FDA Breakthrough Device designation for stage IV metastatic cancer, and European regulatory clearance (CE Mark certification) in 2021 for use in patients with chemo-refractory mTNBC. The LW-02 Immunopheresis Cartridge is currently being evaluated in three global oncology trials for multiple cancers. Immunicom is headquartered in San Diego, CA, with operations in Houston, TX, Philadelphia, PA, Krakow, Poland, and Istanbul, Turkey.
Triumvira Immunologics, Inc. (“Triumvira”) is a clinical-stage company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. The company’s proprietary T cell Antigen Coupler (TAC) technology is a robust and versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies. TAC, our proprietary T cell Antigen Coupler, is a multi-domain chimeric molecule that works directly with the T cell receptor (TCR) to help a T cell recognize and attack cancer cells. The use of an intracellular co-receptor sequence as one of its domains is completely unique to Triumvira. This non-gene edited strategy is designed to retain the T cell’s natural control and internal feedback mechanisms.
We believe TAC will become an essential tool for safely and effectively treating patients with liquid and solid malignancies. The initial target of our TAC-based programs is HER2, a surface cancer antigen frequently over-expressed in a broad range of solid tumors.
Triumvira is headquartered in Austin, Texas with research facilities in Hamilton, Ontario.
Actym Therapeutics, based in Berkeley, CA, is a privately-held biotechnology company focused on discovery and development of novel immuno-oncology therapies to treat cancer. The company has developed an attenuated, microbial-based, immunotherapeutic technology platform called STACT (S. Typhimurium-Attenuated Cancer Therapy). In preclinical studies, STACT specifically enriches in many types of solid tumors and not in healthy tissue. Once there, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells. Many of these payload targets are of significant interest to the biopharmaceutical community but are intractable using conventional approaches due to systemic toxicities after intravenous dosing. Furthermore, STACT has been engineered to deliver payload combinations, which facilitates engagement of multiple biological pathways from a single therapy. In April of 2020, Actym raised $34 million in a Series A financing, co-led by Boehringer-Ingelheim Venture Fund and Panacea Venture Healthcare, with participation from Illumina Ventures, Korea Investment Partners, and JLO Ventures.
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation. Its balanced first-in-class clinical and preclinical portfolio has a diversified risk profile.
Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies, including an innovative platform exclusively licensed from U.Penn to create next-generation cell therapies that are controllable, adaptable and capable of enhancing all CAR approaches.
Prokarium is harnessing evolution to cure difficult to treat cancers by applying cutting edge science at the intersection of immunology and synthetic biology. The company’s mission is to design the perfect bacteria to be the next cancer immunotherapy platform.
AUM Biosciences is at the forefront of disrupting the drug development process in oncology, to deliver pioneering and affordable targeted drugs across a broad spectrum of cancers.
AUM is focused on developing a robust industry leading pipeline of best-in-class and first-in-class small molecule therapies, leveraging the latest in precision and digital medicine tools. Our core mandate of being biomarker driven, using innovative clinical trial designs and utilizing smart data differentiates us from other drug development companies. This enables us to identify innovative, early-stage molecules that can be rapidly progressed into successful and commercially viable drugs treatment.
Codagenix Inc. is a clinical-stage synthetic virology company developing codon-modified live viruses for infectious disease prophylaxis and as virotherapy for cancer.
All of Codagenix’s viruses are rationally designed using the proprietary machine-learning-aided platform SAVE (Synthetic Attenuated Virus Engineering), that exchanges codon usage of selected genes to slow their translation and thereby viral replication. The protein sequence of recoded viruses is identical to the wild-type strain and the resulting viruses retain the full immunostimulatory capacity of the parental virus. Codon-modified live-attenuated viral vaccines for SARS-CoV-2, influenza and RSV have shown excellent safety profiles in phase 1 clinical trials and elicit robust humoral and cellular immune responses.
When injected intratumorally, codon-modified viruses were able to induce anti-tumor immune responses translating to anti-tumor efficacy, tumor regression and long-term survival in preclinical syngeneic mouse models. The lead asset CodaLytic represents a promising immunotherapeutic with the potential to deepen or broaden responses to checkpoint inhibitors and is currently completing IND-enabling studies with clinical development planned in breast cancer indications.
UbiVac is a clinical stage immunotherapy and cancer target discovery company with unique and disruptive immune educating and activating vaccine technology. UbiVac believes that developing durable responses and curative treatments for patients with advanced cancer requires a systems biology approach. Trials with UbiVac’s lead agent, DPV-001, include extensive state-of-the-art immunologic and genetic monitoring of patients (Leidner R.S. AACR 2022). UbiVac postulates that by applying machine learning (ML), artificial intelligence (AI) and generative adversarial networks to the analysis of these patient data will lead to a better understanding of the mechanisms of response and ultimately improve the treatment of cancer by tailoring treatment regimens to meet the patient's specific requirements. UbiVac’s lead agent, DPV-001, contains the newly discovered non-mutated shared cancer antigens and more than 300 antigens for the majority of patients with adenocarcinoma or squamous cell cancers, has been validated by pharma partners, and currently is in a first-in-human immunotherapy triplet trial of our lead agent plus anti-PD-1, +/- anti-GITR. Interim analysis of that trial is expected in 2023. UbiVac is led by an internationally recognized expert in cancer immunotherapy and was spun-out and is closely aligned with a world class immunotherapy center of excellence. UbiVac has a GMP facility to manufacture agents and, based on breakthroughs of the past 12 months that characterized the non-mutated shared cancer antigens, plus preliminary immunological monitoring data from the immunotherapy triplet trial presented at AACR 2022, is preparing for potential expansion of their clinical program in collaboration with several parties. UbiVac is looking for investment to support its expansion, collaboration with pharma and biotech partners, and strategic partnership opportunities in the areas of combination immunotherapy and adoptive cellular immunotherapy of cancer.
ARDAN PHARMA is a Biotech Company dedicated to discover and develop novel drugs for unmet medical needs in oncology. Essentially, our scientific team has over ten years of exhaustive study upon immune system modulation, leading to the creation of a portfolio with potential new oncology drugs. Our technology has synergistic effects with immunotherapies based on the blockade of Immune Checkpoint Blockers as well as with Bcl-2 antagonists. Our interdisciplinary team is therefore committed to transform the treatment of cancer by developing and validating first-in class compounds that target emerging molecular pathways.